The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).
Continue Reading this article here
FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma
